---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-125071"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2025-05-22T23:59:59+00:00"
generated_at: "2026-05-20T19:45:38.853351+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Teva prices $2.3B multi-tranche senior notes offering to refinance existing debt

## Summary
- Upsized offering from $2B to ~$2.3B equivalent across three tranches.
- €1B 4.125% due 2031 (priced 99.349%), $500M 6.000% due 2032 (99.256%), $700M 5.750% due 2030 (99.418%).
- Settlement expected May 28, 2025, subject to customary closing conditions.
- Proceeds to fund tender offers for existing notes with coupons 3.15%-8.125% maturing 2026-2031.
- Net proceeds may also be used for debt repayment at maturity, tender, or redemption.

## SEC filing metadata
- accession: 0001193125-25-125071
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2025-05-22T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000119312525125071/0001193125-25-125071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000119312525125071/d929611d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-125071
- JSON: https://secwatch.observer/filing/0001193125-25-125071.json
- Plain text: https://secwatch.observer/filing/0001193125-25-125071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.